Insider transactions

EDGAR

Hemab Therapeutics Holdings, Inc.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-19.

Open-market purchases (code P)
16 transactions, 2,970,541 shares
Sum of shares × price per share: 55,460,170.87
Open-market sales (code S)
0 transactions, — shares

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–40 of 40

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-09-24 Filed 2026-09-25Walbert Keli Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (36,000) — exercise price 35.72
Acquired (A)36,0000.00
0

Derived: shares × price per share. Exact value 0.00.

36,000Direct (D) No
F1
  • F1 This option was granted on September 24, 2026. The shares underlying the option are scheduled to vest over three years in equal monthly installments from September 24, 2026 through September 24, 2029, subject to continuous service.
Open filing 0001193125-26-402936 Read from the filing’s XML Dispute this row
2026-06-16 Filed 2026-06-17RA CAPITAL MANAGEMENT, L.P. 10% ownerRA Capital Healthcare Fund LP 10% ownerKolchinsky Peter 10% ownerShah Rajeev M. 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)61,52324.98
1,536,844.54

Derived: shares × price per share. Exact value 1536844.54.

6,444,637Indirect (I) See footnotesNo
F4, F2, F3
  • F4 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.65 to $25.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund), RA Capital Nexus II Fund, L.P. (the Nexus Fund II) and RA Capital Nexus IV Fund, L.P. (the Nexus Fund IV). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
  • F3 Held directly by the Fund.
Open filing 0001231919-26-000665 Read from the filing’s XML Dispute this row
2026-06-15 Filed 2026-06-17RA CAPITAL MANAGEMENT, L.P. 10% ownerRA Capital Healthcare Fund LP 10% ownerKolchinsky Peter 10% ownerShah Rajeev M. 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)6,14624.89
152,973.94

Derived: shares × price per share. Exact value 152973.94.

6,383,114Indirect (I) See footnotesNo
F1, F2, F3
  • F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.55 to $25.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund), RA Capital Nexus II Fund, L.P. (the Nexus Fund II) and RA Capital Nexus IV Fund, L.P. (the Nexus Fund IV). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
  • F3 Held directly by the Fund.
Open filing 0001231919-26-000665 Read from the filing’s XML Dispute this row
2026-05-20 Filed 2026-05-21RA CAPITAL MANAGEMENT, L.P. 10% ownerRA Capital Healthcare Fund LP 10% ownerKolchinsky Peter 10% ownerShah Rajeev M. 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)99624.94
24,840.24

Derived: shares × price per share. Exact value 24840.24.

6,376,968Indirect (I) See footnotesNo
F4, F2, F3
  • F4 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.85 to $25.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund), RA Capital Nexus II Fund, L.P. (the Nexus Fund II) and RA Capital Nexus IV Fund, L.P. (the Nexus Fund IV). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
  • F3 Held directly by the Fund.
Open filing 0001231919-26-000521 Read from the filing’s XML Dispute this row
2026-05-19 Filed 2026-05-21RA CAPITAL MANAGEMENT, L.P. 10% ownerRA Capital Healthcare Fund LP 10% ownerKolchinsky Peter 10% ownerShah Rajeev M. 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)3,80224.97
94,935.94

Derived: shares × price per share. Exact value 94935.94.

6,375,972Indirect (I) See footnotesNo
F1, F2, F3
  • F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.86 to $25.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund), RA Capital Nexus II Fund, L.P. (the Nexus Fund II) and RA Capital Nexus IV Fund, L.P. (the Nexus Fund IV). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
  • F3 Held directly by the Fund.
Open filing 0001231919-26-000521 Read from the filing’s XML Dispute this row
2026-05-12 Filed 2026-05-14RA CAPITAL MANAGEMENT, L.P. 10% ownerRA Capital Healthcare Fund LP 10% ownerKolchinsky Peter 10% ownerShah Rajeev M. 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)6,38724.90
159,036.3

Derived: shares × price per share. Exact value 159036.30.

6,372,170Indirect (I) See footnotesNo
F1, F2, F3
  • F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.70 to $25.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund), RA Capital Nexus II Fund, L.P. (the Nexus Fund II) and RA Capital Nexus IV Fund, L.P. (the Nexus Fund IV). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
  • F3 Held directly by the Fund.
Open filing 0001231919-26-000495 Read from the filing’s XML Dispute this row
2026-05-11 Filed 2026-05-11RA CAPITAL MANAGEMENT, L.P. 10% ownerRA Capital Healthcare Fund LP 10% ownerKolchinsky Peter 10% ownerShah Rajeev M. 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)14,14924.47
346,226.03

Derived: shares × price per share. Exact value 346226.03.

6,340,063Indirect (I) See footnotesNo
F6, F2, F3
  • F6 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.93 to $24.90 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund), RA Capital Nexus II Fund, L.P. (the Nexus Fund II) and RA Capital Nexus IV Fund, L.P. (the Nexus Fund IV). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
  • F3 Held directly by the Fund.
Open filing 0001231919-26-000475 Read from the filing’s XML Dispute this row
2026-05-11 Filed 2026-05-11RA CAPITAL MANAGEMENT, L.P. 10% ownerRA Capital Healthcare Fund LP 10% ownerKolchinsky Peter 10% ownerShah Rajeev M. 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)25,72025
643,000

Derived: shares × price per share. Exact value 643000.

6,365,783Indirect (I) See footnotesNo
F7, F2, F3
  • F7 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.93 to $25.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund), RA Capital Nexus II Fund, L.P. (the Nexus Fund II) and RA Capital Nexus IV Fund, L.P. (the Nexus Fund IV). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
  • F3 Held directly by the Fund.
Open filing 0001231919-26-000475 Read from the filing’s XML Dispute this row
2026-05-08 Filed 2026-05-11RA CAPITAL MANAGEMENT, L.P. 10% ownerRA Capital Healthcare Fund LP 10% ownerKolchinsky Peter 10% ownerShah Rajeev M. 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)1,48324.98
37,045.34

Derived: shares × price per share. Exact value 37045.34.

6,325,914Indirect (I) See footnotesNo
F5, F2, F3
  • F5 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.80 to $25.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund), RA Capital Nexus II Fund, L.P. (the Nexus Fund II) and RA Capital Nexus IV Fund, L.P. (the Nexus Fund IV). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
  • F3 Held directly by the Fund.
Open filing 0001231919-26-000475 Read from the filing’s XML Dispute this row
2026-05-07 Filed 2026-05-11RA CAPITAL MANAGEMENT, L.P. 10% ownerRA Capital Healthcare Fund LP 10% ownerKolchinsky Peter 10% ownerShah Rajeev M. 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)7,92124.34
192,797.14

Derived: shares × price per share. Exact value 192797.14.

6,322,446Indirect (I) See footnotesNo
F1, F2, F3
  • F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.775 to $24.685 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund), RA Capital Nexus II Fund, L.P. (the Nexus Fund II) and RA Capital Nexus IV Fund, L.P. (the Nexus Fund IV). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
  • F3 Held directly by the Fund.
Open filing 0001231919-26-000475 Read from the filing’s XML Dispute this row
2026-05-07 Filed 2026-05-11RA CAPITAL MANAGEMENT, L.P. 10% ownerRA Capital Healthcare Fund LP 10% ownerKolchinsky Peter 10% ownerShah Rajeev M. 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)1,98524.95
49,525.75

Derived: shares × price per share. Exact value 49525.75.

6,324,431Indirect (I) See footnotesNo
F4, F2, F3
  • F4 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.84 to $25.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund), RA Capital Nexus II Fund, L.P. (the Nexus Fund II) and RA Capital Nexus IV Fund, L.P. (the Nexus Fund IV). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
  • F3 Held directly by the Fund.
Open filing 0001231919-26-000475 Read from the filing’s XML Dispute this row
2026-05-06 Filed 2026-05-06RA CAPITAL MANAGEMENT, L.P. Director · 10% ownerRA Capital Healthcare Fund LP Director · 10% ownerRA Capital Nexus Fund II, L.P. DirectorRA Capital Nexus Fund IV, L.P. DirectorKolchinsky Peter Director · 10% ownerShah Rajeev M. Director · 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)14,61123.77
347,303.47

Derived: shares × price per share. Exact value 347303.47.

6,261,118Indirect (I) See footnotesNo
F7, F2, F3
  • F7 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.495 to $24.455 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund), RA Capital Nexus II Fund, L.P. (the Nexus Fund II) and RA Capital Nexus IV Fund, L.P. (the Nexus Fund IV). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund II, the Nexus Fund IV, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
  • F3 Held directly by the Fund.
Open filing 0001231919-26-000457 Read from the filing’s XML Dispute this row
2026-05-06 Filed 2026-05-06RA CAPITAL MANAGEMENT, L.P. Director · 10% ownerRA Capital Healthcare Fund LP Director · 10% ownerRA Capital Nexus Fund II, L.P. DirectorRA Capital Nexus Fund IV, L.P. DirectorKolchinsky Peter Director · 10% ownerShah Rajeev M. Director · 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)53,40724.83
1,326,095.81

Derived: shares × price per share. Exact value 1326095.81.

6,314,525Indirect (I) See footnotesNo
F8, F2, F3
  • F8 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.505 to $25.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund), RA Capital Nexus II Fund, L.P. (the Nexus Fund II) and RA Capital Nexus IV Fund, L.P. (the Nexus Fund IV). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund II, the Nexus Fund IV, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
  • F3 Held directly by the Fund.
Open filing 0001231919-26-000457 Read from the filing’s XML Dispute this row
2026-05-05 Filed 2026-05-06RA CAPITAL MANAGEMENT, L.P. Director · 10% ownerRA Capital Healthcare Fund LP Director · 10% ownerRA Capital Nexus Fund II, L.P. DirectorRA Capital Nexus Fund IV, L.P. DirectorKolchinsky Peter Director · 10% ownerShah Rajeev M. Director · 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)87,14324.59
2,142,846.37

Derived: shares × price per share. Exact value 2142846.37.

6,236,239Indirect (I) See footnotesNo
F6, F2, F3
  • F6 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.00 to $24.9994 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund), RA Capital Nexus II Fund, L.P. (the Nexus Fund II) and RA Capital Nexus IV Fund, L.P. (the Nexus Fund IV). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund II, the Nexus Fund IV, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
  • F3 Held directly by the Fund.
Open filing 0001231919-26-000457 Read from the filing’s XML Dispute this row
2026-05-05 Filed 2026-05-06RA CAPITAL MANAGEMENT, L.P. Director · 10% ownerRA Capital Healthcare Fund LP Director · 10% ownerRA Capital Nexus Fund II, L.P. DirectorRA Capital Nexus Fund IV, L.P. DirectorKolchinsky Peter Director · 10% ownerShah Rajeev M. Director · 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)10,26825
256,700

Derived: shares × price per share. Exact value 256700.

6,246,507Indirect (I) See footnotesNo
F2, F3
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund), RA Capital Nexus II Fund, L.P. (the Nexus Fund II) and RA Capital Nexus IV Fund, L.P. (the Nexus Fund IV). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund II, the Nexus Fund IV, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
  • F3 Held directly by the Fund.
Open filing 0001231919-26-000457 Read from the filing’s XML Dispute this row
2026-05-04 Filed 2026-05-06Novo Holdings A/S 10% owner
C

Conversion of derivative security

Common Stock
Acquired (A)4,180,550——4,180,550Direct (D) No
F1
  • F1 Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 22-for-1 basis, and had no expiration date.
Open filing 0001388325-26-000023 Read from the filing’s XML Dispute this row
2026-05-04 Filed 2026-05-06Novo Holdings A/S 10% owner
C

Conversion of derivative security

Derivative security: Series Seed Preferred Stock — underlying Common Stock (513,546)
Disposed (D)23,3430—0Direct (D) No
F1
  • F1 Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 22-for-1 basis, and had no expiration date.
Open filing 0001388325-26-000023 Read from the filing’s XML Dispute this row
2026-05-04 Filed 2026-05-06Novo Holdings A/S 10% owner
C

Conversion of derivative security

Derivative security: Series A Preferred Stock — underlying Common Stock (1,581,052)
Disposed (D)71,8660—0Direct (D) No
F1
  • F1 Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 22-for-1 basis, and had no expiration date.
Open filing 0001388325-26-000023 Read from the filing’s XML Dispute this row
2026-05-04 Filed 2026-05-06Novo Holdings A/S 10% owner
C

Conversion of derivative security

Derivative security: Series B Preferred Stock — underlying Common Stock (1,366,662)
Disposed (D)62,1210—0Direct (D) No
F1
  • F1 Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 22-for-1 basis, and had no expiration date.
Open filing 0001388325-26-000023 Read from the filing’s XML Dispute this row
2026-05-04 Filed 2026-05-06Novo Holdings A/S 10% owner
C

Conversion of derivative security

Derivative security: Series C Preferred Stock — underlying Common Stock (719,290)
Disposed (D)32,6950—0Direct (D) No
F1
  • F1 Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 22-for-1 basis, and had no expiration date.
Open filing 0001388325-26-000023 Read from the filing’s XML Dispute this row
2026-05-04 Filed 2026-05-06RA CAPITAL MANAGEMENT, L.P. Director · 10% ownerRA Capital Healthcare Fund LP Director · 10% ownerRA Capital Nexus Fund II, L.P. DirectorRA Capital Nexus Fund IV, L.P. DirectorKolchinsky Peter Director · 10% ownerShah Rajeev M. Director · 10% owner
C

Conversion of derivative security

Common Stock
Acquired (A)3,607,846——3,607,846Indirect (I) See footnotesNo
F1, F2, F3
  • F1 Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 22-for-1 basis, and had no expiration date.
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund), RA Capital Nexus II Fund, L.P. (the Nexus Fund II) and RA Capital Nexus IV Fund, L.P. (the Nexus Fund IV). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund II, the Nexus Fund IV, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
  • F3 Held directly by the Fund.
Open filing 0001231919-26-000457 Read from the filing’s XML Dispute this row
2026-05-04 Filed 2026-05-06RA CAPITAL MANAGEMENT, L.P. Director · 10% ownerRA Capital Healthcare Fund LP Director · 10% ownerRA Capital Nexus Fund II, L.P. DirectorRA Capital Nexus Fund IV, L.P. DirectorKolchinsky Peter Director · 10% ownerShah Rajeev M. Director · 10% owner
C

Conversion of derivative security

Common Stock
Acquired (A)1,009,052——1,009,052Indirect (I) See footnotesNo
F1, F2, F4
  • F1 Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 22-for-1 basis, and had no expiration date.
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund), RA Capital Nexus II Fund, L.P. (the Nexus Fund II) and RA Capital Nexus IV Fund, L.P. (the Nexus Fund IV). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund II, the Nexus Fund IV, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
  • F4 Held directly by Nexus Fund II.
Open filing 0001231919-26-000457 Read from the filing’s XML Dispute this row
2026-05-04 Filed 2026-05-06RA CAPITAL MANAGEMENT, L.P. Director · 10% ownerRA Capital Healthcare Fund LP Director · 10% ownerRA Capital Nexus Fund II, L.P. DirectorRA Capital Nexus Fund IV, L.P. DirectorKolchinsky Peter Director · 10% ownerShah Rajeev M. Director · 10% owner
C

Conversion of derivative security

Common Stock
Acquired (A)221,188——221,188Indirect (I) See footnotesNo
F1, F2, F5
  • F1 Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 22-for-1 basis, and had no expiration date.
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund), RA Capital Nexus II Fund, L.P. (the Nexus Fund II) and RA Capital Nexus IV Fund, L.P. (the Nexus Fund IV). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund II, the Nexus Fund IV, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
  • F5 Held directly by Nexus Fund IV.
Open filing 0001231919-26-000457 Read from the filing’s XML Dispute this row
2026-05-04 Filed 2026-05-06RA CAPITAL MANAGEMENT, L.P. Director · 10% ownerRA Capital Healthcare Fund LP Director · 10% ownerRA Capital Nexus Fund II, L.P. DirectorRA Capital Nexus Fund IV, L.P. DirectorKolchinsky Peter Director · 10% ownerShah Rajeev M. Director · 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)2,541,25018
45,742,500

Derived: shares × price per share. Exact value 45742500.

6,149,096Indirect (I) See footnotesNo
F2, F3
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund), RA Capital Nexus II Fund, L.P. (the Nexus Fund II) and RA Capital Nexus IV Fund, L.P. (the Nexus Fund IV). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund II, the Nexus Fund IV, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
  • F3 Held directly by the Fund.
Open filing 0001231919-26-000457 Read from the filing’s XML Dispute this row
2026-05-04 Filed 2026-05-06RA CAPITAL MANAGEMENT, L.P. Director · 10% ownerRA Capital Healthcare Fund LP Director · 10% ownerRA Capital Nexus Fund II, L.P. DirectorRA Capital Nexus Fund IV, L.P. DirectorKolchinsky Peter Director · 10% ownerShah Rajeev M. Director · 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)133,75018
2,407,500

Derived: shares × price per share. Exact value 2407500.

354,938Indirect (I) See footnotesNo
F2, F5
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund), RA Capital Nexus II Fund, L.P. (the Nexus Fund II) and RA Capital Nexus IV Fund, L.P. (the Nexus Fund IV). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund II, the Nexus Fund IV, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
  • F5 Held directly by Nexus Fund IV.
Open filing 0001231919-26-000457 Read from the filing’s XML Dispute this row
2026-05-04 Filed 2026-05-06RA CAPITAL MANAGEMENT, L.P. Director · 10% ownerRA Capital Healthcare Fund LP Director · 10% ownerRA Capital Nexus Fund II, L.P. DirectorRA Capital Nexus Fund IV, L.P. DirectorKolchinsky Peter Director · 10% ownerShah Rajeev M. Director · 10% owner
C

Conversion of derivative security

Derivative security: Series A Preferred Stock — underlying Common Stock (1,422,960)
Disposed (D)64,680——0Indirect (I) See footnotesNo
F1, F2, F3
  • F1 Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 22-for-1 basis, and had no expiration date.
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund), RA Capital Nexus II Fund, L.P. (the Nexus Fund II) and RA Capital Nexus IV Fund, L.P. (the Nexus Fund IV). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund II, the Nexus Fund IV, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
  • F3 Held directly by the Fund.
Open filing 0001231919-26-000457 Read from the filing’s XML Dispute this row
2026-05-04 Filed 2026-05-06RA CAPITAL MANAGEMENT, L.P. Director · 10% ownerRA Capital Healthcare Fund LP Director · 10% ownerRA Capital Nexus Fund II, L.P. DirectorRA Capital Nexus Fund IV, L.P. DirectorKolchinsky Peter Director · 10% ownerShah Rajeev M. Director · 10% owner
C

Conversion of derivative security

Derivative security: Series A Preferred Stock — underlying Common Stock (609,840)
Disposed (D)27,720——0Indirect (I) See footnotesNo
F1, F2, F4
  • F1 Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 22-for-1 basis, and had no expiration date.
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund), RA Capital Nexus II Fund, L.P. (the Nexus Fund II) and RA Capital Nexus IV Fund, L.P. (the Nexus Fund IV). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund II, the Nexus Fund IV, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
  • F4 Held directly by Nexus Fund II.
Open filing 0001231919-26-000457 Read from the filing’s XML Dispute this row
2026-05-04 Filed 2026-05-06RA CAPITAL MANAGEMENT, L.P. Director · 10% ownerRA Capital Healthcare Fund LP Director · 10% ownerRA Capital Nexus Fund II, L.P. DirectorRA Capital Nexus Fund IV, L.P. DirectorKolchinsky Peter Director · 10% ownerShah Rajeev M. Director · 10% owner
C

Conversion of derivative security

Derivative security: Series B Preferred Stock — underlying Common Stock (931,502)
Disposed (D)42,341——0Indirect (I) See footnotesNo
F1, F2, F3
  • F1 Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 22-for-1 basis, and had no expiration date.
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund), RA Capital Nexus II Fund, L.P. (the Nexus Fund II) and RA Capital Nexus IV Fund, L.P. (the Nexus Fund IV). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund II, the Nexus Fund IV, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
  • F3 Held directly by the Fund.
Open filing 0001231919-26-000457 Read from the filing’s XML Dispute this row
2026-05-04 Filed 2026-05-06RA CAPITAL MANAGEMENT, L.P. Director · 10% ownerRA Capital Healthcare Fund LP Director · 10% ownerRA Capital Nexus Fund II, L.P. DirectorRA Capital Nexus Fund IV, L.P. DirectorKolchinsky Peter Director · 10% ownerShah Rajeev M. Director · 10% owner
C

Conversion of derivative security

Derivative security: Series B Preferred Stock — underlying Common Stock (399,212)
Disposed (D)18,146——0Indirect (I) See footnotesNo
F1, F2, F4
  • F1 Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 22-for-1 basis, and had no expiration date.
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund), RA Capital Nexus II Fund, L.P. (the Nexus Fund II) and RA Capital Nexus IV Fund, L.P. (the Nexus Fund IV). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund II, the Nexus Fund IV, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
  • F4 Held directly by Nexus Fund II.
Open filing 0001231919-26-000457 Read from the filing’s XML Dispute this row
2026-05-04 Filed 2026-05-06RA CAPITAL MANAGEMENT, L.P. Director · 10% ownerRA Capital Healthcare Fund LP Director · 10% ownerRA Capital Nexus Fund II, L.P. DirectorRA Capital Nexus Fund IV, L.P. DirectorKolchinsky Peter Director · 10% ownerShah Rajeev M. Director · 10% owner
C

Conversion of derivative security

Derivative security: Series C Preferred Stock — underlying Common Stock (1,253,384)
Disposed (D)56,972——0Indirect (I) See footnotesNo
F1, F2, F3
  • F1 Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 22-for-1 basis, and had no expiration date.
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund), RA Capital Nexus II Fund, L.P. (the Nexus Fund II) and RA Capital Nexus IV Fund, L.P. (the Nexus Fund IV). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund II, the Nexus Fund IV, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
  • F3 Held directly by the Fund.
Open filing 0001231919-26-000457 Read from the filing’s XML Dispute this row
2026-05-04 Filed 2026-05-06RA CAPITAL MANAGEMENT, L.P. Director · 10% ownerRA Capital Healthcare Fund LP Director · 10% ownerRA Capital Nexus Fund II, L.P. DirectorRA Capital Nexus Fund IV, L.P. DirectorKolchinsky Peter Director · 10% ownerShah Rajeev M. Director · 10% owner
C

Conversion of derivative security

Derivative security: Series C Preferred Stock — underlying Common Stock (221,188)
Disposed (D)10,054——0Indirect (I) See footnotesNo
F1, F2, F5
  • F1 Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 22-for-1 basis, and had no expiration date.
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund), RA Capital Nexus II Fund, L.P. (the Nexus Fund II) and RA Capital Nexus IV Fund, L.P. (the Nexus Fund IV). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund II, the Nexus Fund IV, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
  • F5 Held directly by Nexus Fund IV.
Open filing 0001231919-26-000457 Read from the filing’s XML Dispute this row
2026-05-04 Filed 2026-05-04MARAGANORE JOHN Director
C

Conversion of derivative security

Common Stock
Acquired (A)17,974——17,974Direct (D) No
F1
  • F1 The warrant was granted on January 29, 2026. The shares underlying the warrant vest over three years in equal monthly installments from January 1, 2026 through January 1, 2029.
Open filing 0001193125-26-204048 Read from the filing’s XML Dispute this row
2026-05-04 Filed 2026-05-04MARAGANORE JOHN Director
C

Conversion of derivative security

Common Stock
Acquired (A)17,974——35,948Direct (D) No
F1
  • F1 The warrant was granted on January 29, 2026. The shares underlying the warrant vest over three years in equal monthly installments from January 1, 2026 through January 1, 2029.
Open filing 0001193125-26-204048 Read from the filing’s XML Dispute this row
2026-05-04 Filed 2026-05-04MARAGANORE JOHN Director
C

Conversion of derivative security

Derivative security: Series B Preferred Stock — underlying Common Stock (17,974)
Disposed (D)8170.00
0

Derived: shares × price per share. Exact value 0.00.

0Direct (D) No
F1, F2
  • F1 The warrant was granted on January 29, 2026. The shares underlying the warrant vest over three years in equal monthly installments from January 1, 2026 through January 1, 2029.
  • F2 Each share of Series B Preferred Stock and Series C Preferred Stock converted into 22 shares of common stock without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
Open filing 0001193125-26-204048 Read from the filing’s XML Dispute this row
2026-05-04 Filed 2026-05-04MARAGANORE JOHN Director
C

Conversion of derivative security

Derivative security: Series C Preferred Stock — underlying Common Stock (17,974)
Disposed (D)8170.00
0

Derived: shares × price per share. Exact value 0.00.

0Direct (D) No
F1, F2
  • F1 The warrant was granted on January 29, 2026. The shares underlying the warrant vest over three years in equal monthly installments from January 1, 2026 through January 1, 2029.
  • F2 Each share of Series B Preferred Stock and Series C Preferred Stock converted into 22 shares of common stock without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
Open filing 0001193125-26-204048 Read from the filing’s XML Dispute this row
2026-04-30 Filed 2026-05-04Behrndt-Eriksen Mads Nikolaj Officer: See Remarks
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (49,016) — exercise price 18.00
Acquired (A)49,0160.00
0

Derived: shares × price per share. Exact value 0.00.

49,016Direct (D) No
F2
  • F2 This option was granted on April 30, 2026. The shares underlying the option will vest over four years in equal monthly installments from May 1, 2026 through May 1, 2030.
Open filing 0001193125-26-204033 Read from the filing’s XML Dispute this row
2026-04-30 Filed 2026-05-04Madigan Catherine Officer: Chief Medical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (49,016) — exercise price 18.00
Acquired (A)49,0160.00
0

Derived: shares × price per share. Exact value 0.00.

49,016Direct (D) No
F2
  • F2 This option was granted on April 30, 2026. The shares underlying the option will vest over four years in equal monthly installments from May 1, 2026 through May 1, 2030.
Open filing 0001193125-26-204041 Read from the filing’s XML Dispute this row
2026-01-29 Filed 2026-05-04Behrndt-Eriksen Mads Nikolaj Officer: See Remarks
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Warrants (Right to Buy) — underlying Common Stock (195,206) — exercise price 6
Acquired (A)195,2060—195,206Direct (D) No
F1
  • F1 The warrant was granted on January 29, 2026. The shares underlying the warrant vest over four years, with 25% of the shares vesting on January 1, 2027 and the remaining shares vesting in equal monthly installments thereafter.
Open filing 0001193125-26-204033 Read from the filing’s XML Dispute this row
2026-01-29 Filed 2026-05-04MARAGANORE JOHN Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Warrants (Right to Buy) — underlying Common Stock (107,338) — exercise price 6
Acquired (A)107,3380—107,338Direct (D) No
F1
  • F1 The warrant was granted on January 29, 2026. The shares underlying the warrant vest over three years in equal monthly installments from January 1, 2026 through January 1, 2029.
Open filing 0001193125-26-204048 Read from the filing’s XML Dispute this row
2026-01-29 Filed 2026-05-04Madigan Catherine Officer: Chief Medical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Warrants (Right to Buy) — underlying Common Stock (145,134) — exercise price 6
Acquired (A)145,1340—145,134Direct (D) No
F1
  • F1 The warrant was granted on January 29, 2026. The shares underlying the warrant vest over four years, with 25% of the shares vesting on January 1, 2027 and the remaining shares vesting in equal monthly installments thereafter.
Open filing 0001193125-26-204041 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 8,905 filings read, the latest filed 2026-11-18. Prior quarter ending 2026-06-30: 9,170 filings read.

Showing 1–50 of 89

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
RA CAPITAL MANAGEMENT, L.P. 7,808,627 SH240,818,057 dollarsUnchanged Prior quarter: 7,808,627Open filing 0001104659-26-128411 Filed 2026-11-16 Dispute this row
NOVO HOLDINGS A/S 4,180,550 SH128,928,162 dollarsUnchanged Prior quarter: 4,180,550Open filing 0001388325-26-000051 Filed 2026-11-16 Dispute this row
FMR LLC Partly reported under another manager3,722,599 SH114,804,954 dollarsHigher by 24,762 Prior quarter: 3,697,837Open filing 0000315066-26-002964 Filed 2026-11-10 Dispute this row
Capital International Investors Partly reported under another manager3,601,463 SH111,069,119 dollarsLower by 2,413 Prior quarter: 3,603,876Open filing 0001562230-26-000136 Filed 2026-11-12 Dispute this row
Deep Track Capital, LP 3,587,796 SH110,647,629 dollarsLower by 14,297 Prior quarter: 3,602,093Open filing 0001856083-26-000006 Filed 2026-11-16 Dispute this row
Siren, L.L.C. Partly reported under another manager2,366,235 SH72,974,687 dollarsHigher by 279,401 Prior quarter: 2,086,834Open filing 0002005245-26-000013 Filed 2026-11-12 Dispute this row
Avoro Capital Advisors LLC 1,892,372 SH58,360,752 dollarsLower by 32,778 Prior quarter: 1,925,150Open filing 0001104659-26-127608 Filed 2026-11-16 Dispute this row
Bain Capital Life Sciences Investors, LLC 1,650,000 SH50,886,000 dollarsUnchanged Prior quarter: 1,650,000Open filing 0001193125-26-462089 Filed 2026-11-16 Dispute this row
BlackRock, Inc. Partly reported under another manager1,399,039 SH43,146,362 dollarsHigher by 1,115,206 Prior quarter: 283,833Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row
JPMORGAN CHASE CO Partly reported under another manager932,857 SH30,411,138 dollarsLower by 219,563 Prior quarter: 1,152,420Open filing 0000019617-26-000404 Filed 2026-11-12 Dispute this row
STATE STREET CORP Partly reported under another manager927,245 SH28,596,236 dollarsHigher by 850,345 Prior quarter: 76,900Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row
VANGUARD CAPITAL MANAGEMENT LLC 774,064 SH23,872,134 dollarsLower by 6,694 Prior quarter: 780,758Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row
PRICE T ROWE ASSOCIATES INC /MD/ Partly reported under another manager757,132 SH23,351 dollarsHigher by 11,092 Prior quarter: 746,040Open filing 0000080255-26-000736 Filed 2026-11-16 Dispute this row
Driehaus Capital Management LLC 708,166 SH21,839,839 dollarsLower by 7,625 Prior quarter: 715,791Open filing 0000938206-26-000066 Filed 2026-11-16 Dispute this row
Paradigm Biocapital Advisors LP 629,347 SH19,409,061 dollarsNot in the prior quarter’s filings read Open filing 0001855655-26-000020 Filed 2026-11-16 Dispute this row
Rock Springs Capital Management LP 575,432 SH17,746,323 dollarsUnchanged Prior quarter: 575,432Open filing 0001172661-26-005279 Filed 2026-11-16 Dispute this row
Bellevue Group AG Partly reported under another manager548,935 SH16,929,155 dollarsLower by 1,065 Prior quarter: 550,000Open filing 0001104659-26-128575 Filed 2026-11-16 Dispute this row
GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager502,042 SH15,486,576 dollarsHigher by 290,244 Prior quarter: 211,798Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row
Affinity Asset Advisors, LLC 420,000 SH12,952,800 dollarsHigher by 281,970 Prior quarter: 138,030Open filing 0001011438-26-000687 Filed 2026-11-13 Dispute this row
Parkman Healthcare Partners LLC 329,251 SH10,154,101 dollarsHigher by 284,251 Prior quarter: 45,000Open filing 0001420506-26-002809 Filed 2026-11-16 Dispute this row
DEERFIELD MANAGEMENT COMPANY, L.P. Partly reported under another manager275,000 SH8,481,000 dollarsUnchanged Prior quarter: 275,000Open filing 0001213900-26-120609 Filed 2026-11-16 Dispute this row
Schonfeld Strategic Advisors LLC 169,101 SH5,215,073 dollarsHigher by 158,288 Prior quarter: 10,813Open filing 0001665241-26-000003 Filed 2026-11-16 Dispute this row
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 164,825 SH5,083,203 dollarsHigher by 56,589 Prior quarter: 108,236Open filing 0000884546-26-000417 Filed 2026-11-16 Dispute this row
NORTHERN TRUST CORP Partly reported under another manager151,558 SH4,674,048 dollarsHigher by 111,071 Prior quarter: 40,487Open filing 0000073124-26-000067 Filed 2026-11-16 Dispute this row
Woodline Partners LP 150,040 SH4,627,234 dollarsUnchanged Prior quarter: 150,040Open filing 0001172661-26-005063 Filed 2026-11-16 Dispute this row
VANGUARD PORTFOLIO MANAGEMENT LLC 137,143 SH4,229,490 dollarsHigher by 128,974 Prior quarter: 8,169Open filing 0002100121-26-001150 Filed 2026-11-13 Dispute this row
VANGUARD FIDUCIARY TRUST CO 124,792 SH3,848,585 dollarsHigher by 12,293 Prior quarter: 112,499Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row
UBS Group AG Partly reported under another manager106,659 SH3,289,364 dollarsHigher by 59,308 Prior quarter: 47,351Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
Ensign Peak Advisors, Inc 96,447 SH2,974,425 dollarsLower by 18,947 Prior quarter: 115,394Open filing 0001454984-26-000011 Filed 2026-11-12 Dispute this row
CITADEL ADVISORS LLC Partly reported under another manager90,412 SH2,788,306 dollarsLower by 433,038 Prior quarter: 523,450Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row
BANK OF AMERICA CORP /DE/ Partly reported under another manager84,934 SH2,619,364 dollarsNot in the prior quarter’s filings read Open filing 0000070858-26-000589 Filed 2026-11-16 Dispute this row
Burkehill Global Management, LP 75,000 SH2,313,000 dollarsUnchanged Prior quarter: 75,000Open filing 0001013594-26-001202 Filed 2026-11-16 Dispute this row
RENAISSANCE TECHNOLOGIES LLC Partly reported under another manager67,542 SH2,082,995 dollarsNot in the prior quarter’s filings read Open filing 0001037389-26-000062 Filed 2026-11-12 Dispute this row
XTX Topco Ltd Partly reported under another manager59,009 SH1,819,838 dollarsHigher by 41,620 Prior quarter: 17,389Open filing 0001828301-26-000009 Filed 2026-11-16 Dispute this row
GOLDMAN SACHS GROUP INC Partly reported under another manager54,602 SH1,683,926 dollarsNot in the prior quarter’s filings read Open filing 0000886982-26-000647 Filed 2026-11-16 Dispute this row
AMERIPRISE FINANCIAL INC Partly reported under another manager53,011 SH1,634,859 dollarsLower by 28,917 Prior quarter: 81,928Open filing 0001193125-26-463125 Filed 2026-11-16 Dispute this row
Quadrature Capital Ltd Partly reported under another manager50,420 SH1,554,953 dollarsNot in the prior quarter’s filings read Open filing 0001651424-26-000014 Filed 2026-11-13 Dispute this row
Bank of New York Mellon Corp Partly reported under another manager45,360 SH1,398,902 dollarsNot in the prior quarter’s filings read Open filing 0001390777-26-000121 Filed 2026-11-05 Dispute this row
Ghisallo Capital Management LLC 40,000 SH1,233,600 dollarsUnchanged Prior quarter: 40,000Open filing 0001172661-26-005189 Filed 2026-11-16 Dispute this row
TD ASSET MANAGEMENT INC 33,098 SH1,078,995 dollarsUnchanged Prior quarter: 33,098Open filing 0001193125-26-460060 Filed 2026-11-13 Dispute this row
Swiss National Bank 30,700 SH946,788 dollarsNot in the prior quarter’s filings read Open filing 0001582202-26-000008 Filed 2026-11-12 Dispute this row
MORGAN STANLEY Partly reported under another manager30,137 SH929,425 dollarsHigher by 26,059 Prior quarter: 4,078Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row
SEVEN GRAND MANAGERS, LLC 30,000 SH925,200 dollarsUnchanged Prior quarter: 30,000Open filing 0001420506-26-002775 Filed 2026-11-16 Dispute this row
Nuveen, LLC Partly reported under another manager29,387 SH906,295 dollarsNot in the prior quarter’s filings read Open filing 0000930413-26-003284 Filed 2026-11-10 Dispute this row
Quantinno Capital Management LP 28,644 SH883,381 dollarsNot in the prior quarter’s filings read Open filing 0001759654-26-000011 Filed 2026-11-13 Dispute this row
GSA CAPITAL PARTNERS LLP 25,104 SH774 dollarsHigher by 7,443 Prior quarter: 17,661Open filing 0001362033-26-000013 Filed 2026-11-16 Dispute this row
MANUFACTURERS LIFE INSURANCE COMPANY, THE Partly reported under another manager24,428 SH753,360 dollarsHigher by 5,708 Prior quarter: 18,720Open filing 0001145443-26-000111 Filed 2026-11-13 Dispute this row
Rafferty Asset Management, LLC 22,349 SH689,243 dollarsNot in the prior quarter’s filings read Open filing 0001999371-26-025241 Filed 2026-11-13 Dispute this row
RHUMBLINE ADVISERS 21,633 SH667,156 dollarsNot in the prior quarter’s filings read Open filing 0001115418-26-000015 Filed 2026-11-10 Dispute this row
Corient Private Wealth LP 20,164 SH621,858 dollarsNot in the prior quarter’s filings read Open filing 0001948780-26-000012 Filed 2026-11-16 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • ExodusPoint Capital Management, LP 218,287 SH
  • BRAIDWELL LP 160,000 SH
  • Sixth Street Partners Management Company, L.P. 108,236 SH
  • Aberdeen Group plc 52,117 SH
  • Opaleye Management Inc. 47,652 SH
  • SOROS FUND MANAGEMENT LLC 25,000 SH
  • LANDSCAPE CAPITAL MANAGEMENT, L.L.C. 13,183 SH
  • Hudson Bay Capital Management LP 12,202 SH
  • Weiss Asset Management LP 10,000 SH
  • Squarepoint Ops LLC 6,252 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
FMR LLC COMMON STOCK10.44,871,850.0010/30/2026 Filed 2026-11-06SCHEDULE 13G/AAmendment 1Open filing 0000315066-26-002938 Dispute this row
Abigail P. Johnson COMMON STOCK10.44,871,850.0010/30/2026 Filed 2026-11-06SCHEDULE 13G/AAmendment 1Open filing 0000315066-26-002938 Dispute this row
Invus Public Equities, L.P. Common Stock, $0.0001 par value per share4.92,295,029.0008/03/2026 Filed 2026-08-07SCHEDULE 13GOpen filing 0002005369-26-000041 Dispute this row
Invus Public Equities Advisors, LLC Common Stock, $0.0001 par value per share4.92,295,029.0008/03/2026 Filed 2026-08-07SCHEDULE 13GOpen filing 0002005369-26-000041 Dispute this row
Invus Global Management, LLC Common Stock, $0.0001 par value per share4.92,295,029.0008/03/2026 Filed 2026-08-07SCHEDULE 13GOpen filing 0002005369-26-000041 Dispute this row
Siren, L.L.C. Common Stock, $0.0001 par value per share4.92,295,029.0008/03/2026 Filed 2026-08-07SCHEDULE 13GOpen filing 0002005369-26-000041 Dispute this row
Avicenna Life Sci Master Fund LP Common Stock, $0.0001 par value per share0.271,206.0008/03/2026 Filed 2026-08-07SCHEDULE 13GOpen filing 0002005369-26-000041 Dispute this row
Avicenna Life Sci Master GP LLC Common Stock, $0.0001 par value per share0.271,206.0008/03/2026 Filed 2026-08-07SCHEDULE 13GOpen filing 0002005369-26-000041 Dispute this row
Ulys, L.L.C. Common Stock, $0.0001 par value per share0.271,206.0008/03/2026 Filed 2026-08-07SCHEDULE 13GOpen filing 0002005369-26-000041 Dispute this row
Raymond Debbane Common Stock, $0.0001 par value per share5.12,366,235.0008/03/2026 Filed 2026-08-07SCHEDULE 13GOpen filing 0002005369-26-000041 Dispute this row
Avoro Capital Advisors LLC Common Stock, par value $0.001 per share4.121,925,150.0006/30/2026 Filed 2026-08-14SCHEDULE 13GOpen filing 0000902664-26-003462 Dispute this row
Avoro Ventures LLC Common Stock, par value $0.001 per share2.941,373,086.0006/30/2026 Filed 2026-08-14SCHEDULE 13GOpen filing 0000902664-26-003462 Dispute this row
Behzad Aghazadeh Common Stock, par value $0.001 per share7.063,298,236.0006/30/2026 Filed 2026-08-14SCHEDULE 13GOpen filing 0000902664-26-003462 Dispute this row
Novo Holdings A/S Common Stock, par value $0.0001 per share9.04,180,550.0006/30/2026 Filed 2026-08-14SCHEDULE 13GOpen filing 0001388325-26-000046 Dispute this row
Capital International Investors Common Stock7.73,603,876.0006/30/2026 Filed 2026-08-12SCHEDULE 13GOpen filing 0001562230-26-000124 Dispute this row
FMR LLC COMMON STOCK7.93,697,837.0006/30/2026 Filed 2026-08-06SCHEDULE 13GOpen filing 0000315066-26-002021 Dispute this row
Abigail P. Johnson COMMON STOCK7.93,697,837.0006/30/2026 Filed 2026-08-06SCHEDULE 13GOpen filing 0000315066-26-002021 Dispute this row
Sofinnova Crossover II SLP Common Stock, par value $0.0001 per share5.42,511,212.0006/30/2026 Filed 2026-08-05SCHEDULE 13GOpen filing 0001104659-26-090835 Dispute this row
Sofinnova Partners SAS, a French corporation Common Stock, par value $0.0001 per share5.42,511,212.0006/30/2026 Filed 2026-08-05SCHEDULE 13GOpen filing 0001104659-26-090835 Dispute this row
Antoine Papiernik Common Stock, par value $0.0001 per share5.42,511,212.0006/30/2026 Filed 2026-08-05SCHEDULE 13GOpen filing 0001104659-26-090835 Dispute this row
Cedric Moreau Common Stock, par value $0.0001 per share5.42,511,212.0006/30/2026 Filed 2026-08-05SCHEDULE 13GOpen filing 0001104659-26-090835 Dispute this row
Kinam Hong Common Stock, par value $0.0001 per share5.42,511,212.0006/30/2026 Filed 2026-08-05SCHEDULE 13GOpen filing 0001104659-26-090835 Dispute this row
Joseph Anderson Common Stock, par value $0.0001 per share5.42,511,212.0006/30/2026 Filed 2026-08-05SCHEDULE 13GOpen filing 0001104659-26-090835 Dispute this row
David Evans Common Stock, par value $0.0001 per share5.42,511,212.0006/30/2026 Filed 2026-08-05SCHEDULE 13GOpen filing 0001104659-26-090835 Dispute this row
RA Capital Management, L.P. Common Stock, par value $0.0001 per share16.67,729,773.0005/04/2026 Filed 2026-05-11SCHEDULE 13GOpen filing 0001346824-26-000127 Dispute this row
Peter Kolchinsky Common Stock, par value $0.0001 per share16.67,729,773.0005/04/2026 Filed 2026-05-11SCHEDULE 13GOpen filing 0001346824-26-000127 Dispute this row
Rajeev Shah Common Stock, par value $0.0001 per share16.67,729,773.0005/04/2026 Filed 2026-05-11SCHEDULE 13GOpen filing 0001346824-26-000127 Dispute this row
RA Capital Healthcare Fund, L.P. Common Stock, par value $0.0001 per share13.66,365,783.0005/04/2026 Filed 2026-05-11SCHEDULE 13GOpen filing 0001346824-26-000127 Dispute this row
AI DEN-MAB LLC Common stock, par value $0.0001 per share10.44,876,34405/04/2026 Filed 2026-05-11SCHEDULE 13DOpen filing 0001193125-26-216973 Dispute this row
Access Industries Holdings LLC Common stock, par value $0.0001 per share10.44,876,34405/04/2026 Filed 2026-05-11SCHEDULE 13DOpen filing 0001193125-26-216973 Dispute this row
AI Biotechnology LLC Common stock, par value $0.0001 per share10.44,876,34405/04/2026 Filed 2026-05-11SCHEDULE 13DOpen filing 0001193125-26-216973 Dispute this row
Access Industries Management LLC Common stock, par value $0.0001 per share10.44,876,34405/04/2026 Filed 2026-05-11SCHEDULE 13DOpen filing 0001193125-26-216973 Dispute this row
Len Blavatnik Common stock, par value $0.0001 per share10.44,876,34405/04/2026 Filed 2026-05-11SCHEDULE 13DOpen filing 0001193125-26-216973 Dispute this row
Deep Track Capital, LP Common stock, $0.0001 par value per share8.153,600,996.0005/01/2026 Filed 2026-05-08SCHEDULE 13GOpen filing 0001172661-26-001639 Dispute this row
Deep Track Biotechnology Master Fund, Ltd. Common stock, $0.0001 par value per share6.752,981,198.0005/01/2026 Filed 2026-05-08SCHEDULE 13GOpen filing 0001172661-26-001639 Dispute this row
David Kroin Common stock, $0.0001 par value per share8.153,600,996.0005/01/2026 Filed 2026-05-08SCHEDULE 13GOpen filing 0001172661-26-001639 Dispute this row
Deep Track Special Opportunities Fund, LP. Common stock, $0.0001 par value per share1.40619,798.0005/01/2026 Filed 2026-05-08SCHEDULE 13GOpen filing 0001172661-26-001639 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,544,215 filings read, dated 2004-06-14 to 2026-11-18: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
201517,857
2016222,642
2017222,009
2018223,345
2019216,482
2020170,508
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026262,403

Filings made before the SEC required XML are listed, not extracted.

Back to Hemab Therapeutics Holdings, Inc.